Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver

Tajima,Hidehiro; Ohta,Tetsuo; Miyashita,Tomoharu; Nakanuma,Shinichi; Matoba,Miki; Miyata,Takashi; Sakai,Seisho; Okamoto,Koichi; Makino,Isamu; Kinoshita,Jun; Hayashi,Hironori; Nakamura,Keishi; Oyama,Katsunobu; Inokuchi,Masafumi; Nakagawara,Hisatoshi; Takamura,Hiroyuki; Kitagawa,Hirohisa; Fushida,Sachio; Ikeda,Hiroko

doi:10.3892/mco.2015.512

Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver

Authors:
- Hidehiro Tajima
- Tetsuo Ohta
- Tomoharu Miyashita
- Shinichi Nakanuma
- Miki Matoba
- Takashi Miyata
- Seisho Sakai
- Koichi Okamoto
- Isamu Makino
- Jun Kinoshita
- Hironori Hayashi
- Keishi Nakamura
- Katsunobu Oyama
- Masafumi Inokuchi
- Hisatoshi Nakagawara
- Hiroyuki Takamura
- Hirohisa Kitagawa
- Sachio Fushida
- Hiroko Ikeda
View Affiliations

Affiliations: Division of Cancer Medicine, Department of Gastroenterologic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa 920‑8641, Japan, Department of Pathology, Kanazawa University Hospital, Kanazawa, Ishikawa 920‑8641, Japan
Published online on: February 16, 2015 https://doi.org/10.3892/mco.2015.512
Pages: 555-558

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxaliplatin‑based chemotherapy plays a central role in the treatment of patients with colorectal liver metastasis (CRLM). This treatment, however, has been associated with hepatic sinusoidal obstruction syndrome (SOS), a clinically important adverse effect characterized by a bluish hue of the liver, splenomegaly and thrombocytopenia, resulting in liver dysfunction. The significant association between the sinusoidal endothelium and platelets has suggested that oxaliplatin‑based chemotherapy affects platelets in the liver. This study compared platelet counts in patients who did and did not receive oxaliplatin‑based neoadjuvant chemotherapy (NAC). The peripheral blood platelet count was significantly lower in the NAC group (n=17) compared to that in the non‑NAC, or control group (n=15) (P<0.05). The spleen index was also higher in the NAC group, although the difference was not significant. However, the spleens of the patients in the NAC group were significantly enlarged following treatment (P<0.01). Immunostaining for the platelet surface marker CD42b (glycoprotein Ib), revealed more platelets in the liver in the NAC compared to the control group, particularly in the centrilobular zone III, adjacent to the hepatic central vein and in contact with hepatocytes (P<0.01). The platelets present in the spaces of Disse, referred to as extravasated platelet aggregation (EPA), secrete a number of growth factors, including transforming growth factor‑β, vascular endothelial growth factor‑A, plasminogen activator inhibitor‑1 and thromboxane A2. In conclusion, EPA may play an important role in the development of hepatic SOS. Moreover, antiplatelet drugs may prevent the onset of SOS and hepatic injury in patients treated with oxaliplatin‑based chemotherapy for CRLM.

View Figures

View References

1	Rubbia-Brandt L, Audard V, Sartoretti P, et al: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 15:460–466. 2004. View Article : Google Scholar : PubMed/NCBI
2	Hubert C, Fervaille C, Sempoux C, et al: Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery. 147:185–194. 2010. View Article : Google Scholar : PubMed/NCBI
3	Vauthey JN, Pawlik TM, Ribero D, et al: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 24:2065–2072. 2006. View Article : Google Scholar : PubMed/NCBI
4	Tamandl D, Klinger M, Eipeldauer S, et al: Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 18:421–430. 2011. View Article : Google Scholar : PubMed/NCBI
5	Robinson SM, Wilson CH, Burt AD, Manas DM and White SA: Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol. 19:4287–4299. 2012. View Article : Google Scholar : PubMed/NCBI
6	Aloysius MM, Zaitoun AM, Beckingham IJ, et al: The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. Virchows Arch. 451:943–948. 2007. View Article : Google Scholar : PubMed/NCBI
7	Nakano H, Oussoultzoglou E, Rosso E, et al: Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 247:118–124. 2008. View Article : Google Scholar : PubMed/NCBI
8	Jardim DL, Rodrigues CA, Novis YAS, Rocha VG and Hoff PM: Oxaliplatin-related thrombocytopenia. Ann Oncol. 23:1937–1942. 2012. View Article : Google Scholar : PubMed/NCBI
9	Miura K, Nakano H, Sakurai J, et al: Splenomegaly in FOLFOX-naive stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Oncol. 16:257–263. 2011. View Article : Google Scholar
10	Krieger PM, Tamandl D, Herberger B, et al: Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann Surg Oncol. 18:1644–1650. 2011. View Article : Google Scholar : PubMed/NCBI
11	Sato S, Nakano H, Ishida Y and Otsubo T: The aspartate aminotransferase to platelet ratio before chemotherapy predicts adverse events for FOLFOX and XELOX regimens including bevacizumab as the first-line therapy for stage IV, recurrent and metastatic colorectal cancer. J Gastrointest Oncol. 4:203–209. 2013.PubMed/NCBI
12	Narita M, Oussoultzoglou E, Chenard MP, et al: Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol. 19:2230–2237. 2012. View Article : Google Scholar : PubMed/NCBI
13	Morine Y, Shimada M and Utsunomiya T: Evaluation and management of hepatic injury induced by oxaliplatin-based chemotherapy in patients with hepatic resection for colorectal liver metastasis. Hepatol Res. 44:59–69. 2014. View Article : Google Scholar : PubMed/NCBI
14	Lalor PF, Herbert J, Bicknell R and Adams DH: Hepatic sinusoidal endothelium avidly binds platelets in an integrin-dependent manner, leading to platelet and endothelial activation and leukocyte recruitment. Am J Physiol Gastrointest Liver Physiol. 304:G469–G478. 2013. View Article : Google Scholar : PubMed/NCBI
15	Koga T: Correlation between sectional area of the spleen by ultrasonic tomography and actual volume of the removed spleen. J Clin Ultrasound. 7:119–120. 1979. View Article : Google Scholar : PubMed/NCBI
16	Campos-Varela I, Castells L, Dopazo C, et al: Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl. 18:201–205. 2012. View Article : Google Scholar : PubMed/NCBI
17	Taaning E: Platelet immunology. ELISA for detection of platelet antibodies, platelet-specific antigens and platelet glycoproteins. Dan Med Bull. 39:343–354. 1992.PubMed/NCBI
18	Battinelli EM, Markens BA and Italiano JE: Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 118:1359–1369. 2011. View Article : Google Scholar : PubMed/NCBI
19	Cui S, Shibamoto T, Liu W, Takano H and Kurata Y: Effects of platelet-activating factor, thromboxane A2 and leukotriene D4 on isolated perfused rat liver. Prostaglandins Other Lipid Mediat. 80:35–45. 2006. View Article : Google Scholar : PubMed/NCBI
20	Venkatraman L, Chia SM, Narmada BC, et al: Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1. Biophys J. 103:1060–1068. 2012. View Article : Google Scholar : PubMed/NCBI
21	Narmada BC, Chia SM, Tucker-Kellogg L and Yu H: HGF regulates the activation of TGF-β1 in rat hepatocytes and hepatic stellate cells. J Cell Physiol. 228:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
22	Parenti A, Brogelli L, Filippi S, Donnini S and Ledda F: Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. Cardiovasc Res. 55:201–212. 2002. View Article : Google Scholar : PubMed/NCBI
23	Ribero D, Wang H, Donadon M, et al: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 110:2761–2767. 2007. View Article : Google Scholar : PubMed/NCBI
24	Rubbia-Brandt L, Lauwers GY, Wang H, et al: Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Hepatology. 56:430–439. 2010.
25	van der Pool AEM, Marsman HA, Verheij J, et al: Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. J Surg Oncol. 106:892–897. 2012. View Article : Google Scholar : PubMed/NCBI